Patents by Inventor Michael R. Freeman

Michael R. Freeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10254285
    Abstract: The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes and contents of the large oncosomes in a subject in need thereof. Also provided herein are methods for treating cancer metastasis by specifically targeting contents of the large oncosomes.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 9, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dolores Di Vizio, Michael R. Freeman, Matteo Morello, Valentina R. Minciacchi
  • Publication number: 20160061842
    Abstract: The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes and contents of the large oncosomes in a subject in need thereof. Also provided herein are methods for treating cancer metastasis by specifically targeting contents of the large oncosomes.
    Type: Application
    Filed: October 14, 2015
    Publication date: March 3, 2016
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dolores Di Vizio, Michael R. Freeman, Matteo Morello, Valentina R. Minciacchi
  • Publication number: 20150037814
    Abstract: Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions.
    Type: Application
    Filed: March 6, 2014
    Publication date: February 5, 2015
    Applicant: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Michael R. Freeman, Dmitri Wiederschain
  • Publication number: 20140178893
    Abstract: Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions.
    Type: Application
    Filed: July 16, 2013
    Publication date: June 26, 2014
    Inventors: Marsha A. Moses, Michael R. Freeman, Dmitri Wiederschain
  • Publication number: 20140056807
    Abstract: The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes in a subject in need thereof.
    Type: Application
    Filed: August 23, 2013
    Publication date: February 27, 2014
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dolores Di Vizio, Michael R. Freeman, Matteo Morello
  • Publication number: 20090208448
    Abstract: Cholesterol-uptake-blocking drugs inhibit angiogenesis and are useful to inhibit diseases perpetuated by angiogenesis. Cholesterol reduction with the use of the drugs increases the intratumoral level of thrombospondin-1, an angiogenesis inhibitor. Ezetimibe (Zetia®), a specific cholesterol-uptake blocking drug, also retards the growth of human tumors, most preferably in combination with low-cholesterol diet. The pharmacologic reduction in serum cholesterol retards prostate cancer growth by inhibiting tumor angiogenesis to combat the growth of prostatic tumors which are directly accelerated by hypercholesterolemia.
    Type: Application
    Filed: February 12, 2009
    Publication date: August 20, 2009
    Inventors: Keith R. Solomon, Kristine Pelton, Carl P. Schaffner, Michael R. Freeman
  • Patent number: 7449453
    Abstract: A method of prevention or treatment of a cholesterol-associated tumor is provided which comprises administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe (SCH 58235) and/or its phenolic glucuronide, or at least one ezetimibe analog, e.g., SCH 48461 and SCH 58053, to a patient wherein the patient is either at risk of developing a cholesterol-associated tumor or already exhibits a cholesterol-associated tumor. Formulations of ezetimibe are also provided for the prevention or treatment of a cholesterol-associated tumor further comprising at least one other anticancer agent.
    Type: Grant
    Filed: July 13, 2006
    Date of Patent: November 11, 2008
    Assignees: Karykion Inc., Children's Medical Center Corporation
    Inventors: Carl P. Schaffner, Keith R. Solomon, Michael R. Freeman
  • Patent number: 6933292
    Abstract: A method of prevention or treatment of a cholesterol-associated tumor is provided which comprises administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe (SCH 58235) and/or its phenolic glucuronide, or at least one ezetimibe analog, e.g., SCH 48461 and SCH 58053, to a patient wherein the patient is either at risk of developing a cholesterol-associated tumor or already exhibits a cholesterol-associated tumor. Formulations of ezetimibe are also provided for the prevention or treatment of a cholesterol-associated tumor further comprising at least one other anticancer agent.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: August 23, 2005
    Assignee: Children's Medical Center Corporation
    Inventors: Carl P. Schaffner, Keith R. Solomon, Michael R. Freeman
  • Patent number: 6811995
    Abstract: The present invention relates to non-invasive methods for facilitating the diagnosis of a subject as having cancer. The described methods involve detecting the presence of a matrix metalloproteinase in urine samples obtained from a patient and correlating the presence or absence of the matrix metalloproteinase with the presence or absence of cancer. Methods for monitoring the prognosis of a patient by detection of matrix metalloproteinase are also provided.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: November 2, 2004
    Assignee: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Michael R. Freeman, Dmitri Wiederschain
  • Publication number: 20040116358
    Abstract: A method of prevention or treatment of a cholesterol-associated tumor is provided which comprises administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe (SCH 58235) and/or its phenolic glucuronide, or at least one ezetimibe analog, e.g., SCH 48461 and SCH 58053, to a patient wherein the patient is either at risk of developing a cholesterol-associated tumor or already exhibits a cholesterol-associated tumor. Formulations of ezetimibe are also provided for the prevention or treatment of a cholesterol-associated tumor further comprising at least one other anticancer agent.
    Type: Application
    Filed: July 30, 2003
    Publication date: June 17, 2004
    Inventors: Carl P. Schaffner, Keith R. Solomon, Michael R. Freeman
  • Publication number: 20030215900
    Abstract: Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions.
    Type: Application
    Filed: April 16, 2003
    Publication date: November 20, 2003
    Inventors: Marsha A. Moses, Michael R. Freeman, Dmitri Wiederschain
  • Patent number: 6037138
    Abstract: Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: March 14, 2000
    Assignee: The Children's Medical Center Corp.
    Inventors: Marsha A. Moses, Michael R. Freeman, Dmitri Wiederschain
  • Patent number: 5567612
    Abstract: Methods and artificial matrices for the growth and implantation of urological structures and surfaces are disclosed in which urothelial cells are grown in culture on biodegradable, biocompatible, fibrous matrices formed of polymers, such as polyglycolic acid, polylactic acid, or other polymers which degrade over time. The cells can be cultured in vitro until an adequate cell volume and density has developed for the cells to survive and proliferate in vivo. Alternatively, when adequate cell numbers for implantation are available, the cells can be attached to the matrix and implanted directly, without proliferation in vitro. The implants approximate the desired urological structure to be replaced or repaired, such as the kidney, urether, bladder, urethra, and the like. Implantation is followed by remodeling through cell growth and proliferation in vivo.
    Type: Grant
    Filed: July 27, 1993
    Date of Patent: October 22, 1996
    Assignees: Massachusetts Institute of Technology, Children's Medical Center Corporation
    Inventors: Joseph P. Vacanti, Michael R. Freeman